Impact of liraglutide on albumin-to-creatinine ratio in type 2 diabetes mellitus: a meta-analysis.

Wang F, Xu G, Feng W, Qu G, Li P, Li K

European journal of medical research22 Jul 2025

PMID40696486PMCIDPMC12281775DOI10.1186/s40001-025-02801-2PepBankPUB-40696486

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study11

4 results from studies that gave the peptide. 4 results from people.

01HumanSystematic reviewEfficacy outcome
In patients with T2DM, liraglutide significantly reduced ACR versus placebo or active-drug controls (WMD -11.76 mg/g, 95% CI -21.71 to -1.81, P=0.02; I2=75%).
In plain wordsIn people with type 2 diabetes, liraglutide lowered albumin-to-creatinine ratio versus controls.
Peptide
Liraglutide
Outcome
Decreasealbumin-to-creatinine ratio
Study
n = 473
Comparator
controls (placebo or active drugs)
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated
Measurements
WMD
−11.76 mg/g
liraglutide versus placebo or active-drug controls
95% CI
−21.71 to −1.81 mg/g
pooled ACR contrast
P-value
0.02
pooled ACR contrast
I2
75%
heterogeneity of pooled ACR contrast
Source sentences
Summary
Liraglutide significantly reduced ACR (WMD: - 11.76 mg/g, 95% CI, - 21.71 to - 1.81, I² = 75%, P = 0.02) compared to controls (placebo or active drugs).
4 context sentences(design, population, supporting numbers)
Summary · context
This study aimed to ascertain the impact of liraglutide on ACR in T2DM.
Summary · context
PubMed, Embase, the Cochrane Library, WanFang and CNKI were searched for randomized controlled trials (RCTs) from inception to November 30, 2024 (PROSPERO: CRD52025336785).
Summary · context
The data were pooled using fixed- or random-effects models based on the heterogeneity.
Summary · context
Seven RCTs involving 473 participants were included.
Report a problemFND-4069648601
02HumanSystematic reviewEfficacy outcome
In T2DM meta-analysis subgroups with HbA1c above 8.0%, liraglutide significantly reduced ACR; the subgroup-specific comparison and analyzed N were unstated.
In plain wordsIn T2D subgroups with HbA1c above 8.0%, liraglutide significantly lowered albumin-to-creatinine ratio; the exact comparison was unspecified.
Peptide
Liraglutide
Outcome
Decreasealbumin-to-creatinine ratio in HbA1c above 8.0%
Study
n: not reported in source
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated
Source sentences
Summary
Subgroup analysis revealed significant ACR reductions in patients with HbA1c > 8.0%, follow-up > 12 weeks, and age < 60 years.
3 context sentences(design, population, supporting numbers)
Summary · context
This study aimed to ascertain the impact of liraglutide on ACR in T2DM.
Summary · context
PubMed, Embase, the Cochrane Library, WanFang and CNKI were searched for randomized controlled trials (RCTs) from inception to November 30, 2024 (PROSPERO: CRD52025336785).
Summary · context
The data were pooled using fixed- or random-effects models based on the heterogeneity.
Report a problemFND-4069648602
03HumanSystematic reviewEfficacy outcome
In T2DM meta-analysis subgroups with follow-up over 12 weeks, liraglutide significantly reduced ACR; the subgroup-specific comparison and analyzed N were unstated.
In plain wordsIn T2D subgroups with follow-up over 12 weeks, liraglutide significantly lowered albumin-to-creatinine ratio; the exact comparison was unspecified.
Peptide
Liraglutide
Outcome
Decreasealbumin-to-creatinine ratio with follow-up over 12 weeks
Study
n: not reported in source
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated
Source sentences
Summary
Subgroup analysis revealed significant ACR reductions in patients with HbA1c > 8.0%, follow-up > 12 weeks, and age < 60 years.
3 context sentences(design, population, supporting numbers)
Summary · context
This study aimed to ascertain the impact of liraglutide on ACR in T2DM.
Summary · context
PubMed, Embase, the Cochrane Library, WanFang and CNKI were searched for randomized controlled trials (RCTs) from inception to November 30, 2024 (PROSPERO: CRD52025336785).
Summary · context
The data were pooled using fixed- or random-effects models based on the heterogeneity.
Report a problemFND-4069648603
04HumanSystematic reviewEfficacy outcome
In T2DM meta-analysis subgroups with age younger than 60 years, liraglutide significantly reduced ACR; the subgroup-specific comparison and analyzed N were unstated.
In plain wordsIn T2D subgroups with age below 60, liraglutide significantly lowered albumin-to-creatinine ratio; the exact comparison was unspecified.
Peptide
Liraglutide
Outcome
Decreasealbumin-to-creatinine ratio in patients younger than 60 years
Study
n: not reported in source
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated
Source sentences
Summary
Subgroup analysis revealed significant ACR reductions in patients with HbA1c > 8.0%, follow-up > 12 weeks, and age < 60 years.
3 context sentences(design, population, supporting numbers)
Summary · context
This study aimed to ascertain the impact of liraglutide on ACR in T2DM.
Summary · context
PubMed, Embase, the Cochrane Library, WanFang and CNKI were searched for randomized controlled trials (RCTs) from inception to November 30, 2024 (PROSPERO: CRD52025336785).
Summary · context
The data were pooled using fixed- or random-effects models based on the heterogeneity.
Report a problemFND-4069648604

Studies that did not test the peptide alone7

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

05HumanNot a test of Liraglutide aloneSystematic reviewOther
In the T2DM liraglutide ACR meta-regression, heterogeneity was reported uninfluenced by sample size; the source reported P=0.92 and 95% CI -322.34 to 340.66 for the listed factors without parameter-specific mapping.
In plain wordsIn the T2D liraglutide review, heterogeneity was reportedly uninfluenced by sample size; the exact parameter-specific comparison was unstated.
Peptide
Liraglutide
Outcome
No significant changeACR meta-regression heterogeneity association with sample size
Study
n: not reported in source
Outcome group
Overall treatment effect · Pharmacology
Measurements
Reported meta-regression P-value
0.92
source list; not assigned to this factor alone
95% CI
−322.34 to 340.66
source interval; parameter mapping unstated
Source sentences
Summary
Meta regression indicated that heterogeneity was not influenced by sample size, HbA1c, baseline ACR, treatment duration, or liraglutide dosage (P = 0.92; 95% CI, - 322.34 to 340.66).
3 context sentences(design, population, supporting numbers)
Summary · context
This study aimed to ascertain the impact of liraglutide on ACR in T2DM.
Summary · context
PubMed, Embase, the Cochrane Library, WanFang and CNKI were searched for randomized controlled trials (RCTs) from inception to November 30, 2024 (PROSPERO: CRD52025336785).
Summary · context
The data were pooled using fixed- or random-effects models based on the heterogeneity.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4069648605
06HumanNot a test of Liraglutide aloneSystematic reviewOther
In the T2DM liraglutide ACR meta-regression, heterogeneity was reported uninfluenced by HbA1c; the source reported P=0.92 and 95% CI -322.34 to 340.66 for the listed factors without parameter-specific mapping.
In plain wordsIn the T2D liraglutide review, heterogeneity was reportedly uninfluenced by HbA1c; the exact parameter-specific comparison was unstated.
Peptide
Liraglutide
Outcome
No significant changeACR meta-regression heterogeneity association with HbA1c
Study
n: not reported in source
Outcome group
Overall treatment effect · Pharmacology
Measurements
Reported meta-regression P-value
0.92
source list; not assigned to this factor alone
95% CI
−322.34 to 340.66
source interval; parameter mapping unstated
Source sentences
Summary
Meta regression indicated that heterogeneity was not influenced by sample size, HbA1c, baseline ACR, treatment duration, or liraglutide dosage (P = 0.92; 95% CI, - 322.34 to 340.66).
3 context sentences(design, population, supporting numbers)
Summary · context
This study aimed to ascertain the impact of liraglutide on ACR in T2DM.
Summary · context
PubMed, Embase, the Cochrane Library, WanFang and CNKI were searched for randomized controlled trials (RCTs) from inception to November 30, 2024 (PROSPERO: CRD52025336785).
Summary · context
The data were pooled using fixed- or random-effects models based on the heterogeneity.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4069648606
07HumanNot a test of Liraglutide aloneSystematic reviewOther
In the T2DM liraglutide ACR meta-regression, heterogeneity was reported uninfluenced by baseline ACR; the source reported P=0.92 and 95% CI -322.34 to 340.66 for the listed factors without parameter-specific mapping.
In plain wordsIn the T2D liraglutide review, heterogeneity was reportedly uninfluenced by baseline ACR; the exact parameter-specific comparison was unstated.
Peptide
Liraglutide
Outcome
No significant changeACR meta-regression heterogeneity association with baseline ACR
Study
n: not reported in source
Outcome group
Overall treatment effect · Pharmacology
Measurements
Reported meta-regression P-value
0.92
source list; not assigned to this factor alone
95% CI
−322.34 to 340.66
source interval; parameter mapping unstated
Source sentences
Summary
Meta regression indicated that heterogeneity was not influenced by sample size, HbA1c, baseline ACR, treatment duration, or liraglutide dosage (P = 0.92; 95% CI, - 322.34 to 340.66).
3 context sentences(design, population, supporting numbers)
Summary · context
This study aimed to ascertain the impact of liraglutide on ACR in T2DM.
Summary · context
PubMed, Embase, the Cochrane Library, WanFang and CNKI were searched for randomized controlled trials (RCTs) from inception to November 30, 2024 (PROSPERO: CRD52025336785).
Summary · context
The data were pooled using fixed- or random-effects models based on the heterogeneity.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4069648607
08HumanNot a test of Liraglutide aloneSystematic reviewOther
In the T2DM liraglutide ACR meta-regression, heterogeneity was reported uninfluenced by treatment duration; the source reported P=0.92 and 95% CI -322.34 to 340.66 for the listed factors without parameter-specific mapping.
In plain wordsIn the T2D liraglutide review, heterogeneity was reportedly uninfluenced by treatment duration; the exact parameter-specific comparison was unstated.
Peptide
Liraglutide
Outcome
No significant changeACR meta-regression heterogeneity association with treatment duration
Study
n: not reported in source
Outcome group
Overall treatment effect · Pharmacology
Measurements
Reported meta-regression P-value
0.92
source list; not assigned to this factor alone
95% CI
−322.34 to 340.66
source interval; parameter mapping unstated
Source sentences
Summary
Meta regression indicated that heterogeneity was not influenced by sample size, HbA1c, baseline ACR, treatment duration, or liraglutide dosage (P = 0.92; 95% CI, - 322.34 to 340.66).
3 context sentences(design, population, supporting numbers)
Summary · context
This study aimed to ascertain the impact of liraglutide on ACR in T2DM.
Summary · context
PubMed, Embase, the Cochrane Library, WanFang and CNKI were searched for randomized controlled trials (RCTs) from inception to November 30, 2024 (PROSPERO: CRD52025336785).
Summary · context
The data were pooled using fixed- or random-effects models based on the heterogeneity.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4069648608
09HumanNot a test of Liraglutide aloneSystematic reviewOther
In the T2DM liraglutide ACR meta-regression, heterogeneity was reported uninfluenced by liraglutide dosage; the source reported P=0.92 and 95% CI -322.34 to 340.66 for the listed factors without parameter-specific mapping.
In plain wordsIn the T2D liraglutide review, heterogeneity was reportedly uninfluenced by liraglutide dosage; the exact parameter-specific comparison was unstated.
Peptide
Liraglutide
Outcome
No significant changeACR meta-regression heterogeneity association with liraglutide dosage
Study
n: not reported in source
Outcome group
Overall treatment effect · Pharmacology
Measurements
Reported meta-regression P-value
0.92
source list; not assigned to this factor alone
95% CI
−322.34 to 340.66
source interval; parameter mapping unstated
Source sentences
Summary
Meta regression indicated that heterogeneity was not influenced by sample size, HbA1c, baseline ACR, treatment duration, or liraglutide dosage (P = 0.92; 95% CI, - 322.34 to 340.66).
3 context sentences(design, population, supporting numbers)
Summary · context
This study aimed to ascertain the impact of liraglutide on ACR in T2DM.
Summary · context
PubMed, Embase, the Cochrane Library, WanFang and CNKI were searched for randomized controlled trials (RCTs) from inception to November 30, 2024 (PROSPERO: CRD52025336785).
Summary · context
The data were pooled using fixed- or random-effects models based on the heterogeneity.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4069648609
10HumanNot a test of Liraglutide aloneSystematic reviewOther
In the T2DM liraglutide ACR meta-analysis, results were stable in sensitivity analysis; the specific sensitivity contrasts and analyzed subsets were unstated.
In plain wordsIn the T2D liraglutide review, results remained stable in sensitivity checks; the exact comparisons were unspecified.
Peptide
Liraglutide
Outcome
Not applicableACR sensitivity-analysis stability
Study
n: not reported in source
Outcome group
Overall treatment effect · Pharmacology
Source sentences
Summary
The results were stable based in sensitivity analysis, and no publication bias was detected (Begg's P = 0.46; Egger's P = 0.57).
3 context sentences(design, population, supporting numbers)
Summary · context
This study aimed to ascertain the impact of liraglutide on ACR in T2DM.
Summary · context
PubMed, Embase, the Cochrane Library, WanFang and CNKI were searched for randomized controlled trials (RCTs) from inception to November 30, 2024 (PROSPERO: CRD52025336785).
Summary · context
The data were pooled using fixed- or random-effects models based on the heterogeneity.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4069648610
11HumanNot a test of Liraglutide aloneSystematic reviewOther
In the T2DM liraglutide ACR meta-analysis, no publication bias was detected (Begg's P=0.46; Egger's P=0.57); the comparison was an analysis-quality assessment.
In plain wordsIn the T2D liraglutide review, statistical checks detected no publication bias; this was an analysis-quality result.
Peptide
Liraglutide
Outcome
No significant changeACR publication-bias assessment
Study
n: not reported in source
Outcome group
Overall treatment effect · Pharmacology
Measurements
Begg's P-value
0.46
publication-bias test
Egger's P-value
0.57
publication-bias test
Source sentences
Summary
The results were stable based in sensitivity analysis, and no publication bias was detected (Begg's P = 0.46; Egger's P = 0.57).
3 context sentences(design, population, supporting numbers)
Summary · context
This study aimed to ascertain the impact of liraglutide on ACR in T2DM.
Summary · context
PubMed, Embase, the Cochrane Library, WanFang and CNKI were searched for randomized controlled trials (RCTs) from inception to November 30, 2024 (PROSPERO: CRD52025336785).
Summary · context
Sensitivity analyses and publication bias assessments were performed.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4069648611

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.